Clinical trials
SLE (Systemic Lupus) clinical trials
Below are recruiting sle (systemic lupus) clinical trials, each written for real people, not researchers. We’re tracking 217 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04604990Recruiting
National lupus patient study for adults in Saudi Arabia
This study follows adults with systemic lupus erythematosus (lupus) to better understand the condition over time. If you meet common lupus diagnosis standards, you may be able to join—there’s no limit on when you were diagnosed.
Riyadh, Central ProvinceAges 19 years+ - NCT07855302RecruitingPhase 1
CAR T-cell therapy for young people with lupus
This trial tests a treatment that uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. It is for young people whose lupus is active despite trying several standard treatments.
SeoulAges Up to 25 years - NCT07829614RecruitingPhase 1
F182112 study for people with lupus
This study tests a new drug called F182112 for people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body. The drug targets certain immune cells to possibly reduce lupus symptoms.
ShanghaiAges 18–65 - NCT07800871RecruitingPhase 1/Phase 2
FT839 cell therapy for autoimmune diseases
This trial tests a new cell therapy (FT839) designed to target and reset the immune system's B cells to help treat moderate to severe autoimmune diseases that haven't improved with standard treatments. It's an early-phase study, so the main goals are to see if it's safe and if it helps control the disease.
Fullerton, CaliforniaAges 18–70 - NCT07760480RecruitingPhase 4
Intensified treatment for lupus nephritis
This study tests whether adding a drug called voclosporin to the usual treatment for lupus nephritis (a kidney disease caused by lupus) can better reduce kidney inflammation. It also looks at the role of immune cells in this process.
AmsterdamAges 16–70 - NCT07720310Enrolling by invitation
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
Lyasny, Minsk OblastAges 18–70 - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT07713940Recruiting
Anti-inflammatory diet study for lupus patients
This study tests whether an anti-inflammatory diet can help people with lupus who are on certain medications. It focuses on reducing pain and improving quality of life over 12 weeks.
La Jolla, CaliforniaAges 18 years+ - NCT07679776Enrolling by invitation
Study on early vision changes in lupus patients
This study looks at whether people with systemic lupus erythematosus (SLE) have early signs of vision problems. Eye tests will be used to check how well you see and if there are any hidden issues in your eyes.
Hefei, AnhuiAges Any age - NCT06675422RecruitingPhase 1/Phase 2
JY231 injection for active lupus
This trial tests an investigational drug called JY231 for people with active systemic lupus erythematosus (SLE) that is not well controlled with standard treatments. The goal is to see if JY231 can reduce lupus activity and improve symptoms.
Kunming, YunnanAges 14–75 - NCT07617740RecruitingEarly Phase 1
IASO207 cell therapy for treatment-resistant lupus
This early-stage trial tests IASO207, a new cell therapy designed to help people with severe lupus that hasn't improved with standard medications. The therapy works by modifying immune cells to reduce lupus activity.
BeijingAges 18–75 - NCT07607964RecruitingPhase 1
ABBV-519 Study for Lupus or Rheumatoid Arthritis
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
Anniston, AlabamaAges 18–75 - NCT07598396RecruitingPhase 2
Mosunetuzumab for systemic lupus erythematosus treatment
This study tests a new drug called mosunetuzumab in people with systemic lupus erythematosus (SLE), a disease where the immune system attacks the body's own tissues. The drug is designed to help control the immune response and reduce lupus symptoms, including kidney involvement if present.
Salvador, Estado de BahiaAges 18 years+ - NCT07570862RecruitingPhase 2
CAR T-Cell Therapy for Hard-to-Treat Lupus Kidney Disease
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Beverly Hills, CaliforniaAges 12–70 - NCT07575347Recruiting
Gum Disease and Rare Kidney Disorders Study
This study explores whether people with certain rare kidney diseases or chronic kidney problems have more gum disease than others. Researchers will examine your teeth and gums to understand the connection and help improve care for people with kidney conditions.
BucharestAges 18 years+ - NCT07564596RecruitingPhase 1/Phase 2
A Study of Budoprutug for Systemic Lupus Erythematosus
This trial tests budoprutug, an experimental drug, to see if it helps people with systemic lupus erythematosus (SLE) whose disease is not well controlled by current treatments. The drug targets immune cells that may be driving the disease.
Mianyang, SichuanAges 18–65 - NCT07490041RecruitingEarly Phase 1
CAR-NK cell therapy for refractory childhood rheumatic diseases
This trial is testing a new type of cell therapy (CAR-NK cells) that targets two markers on immune cells (CD19 and BCMA) to treat severe forms of childhood rheumatic diseases. It aims to see if this treatment is safe and can help when other medicines have failed.
Hangzhou, ZhejiangAges 5 years+ - NCT07491900RecruitingPhase 1
Study of HB2198 for lupus with moderate to severe symptoms
This trial tests a new drug called HB2198 to see if it can help people with moderate to severe lupus. It may be an option for those whose current treatments haven't worked well enough.
BrisbaneAges 18–65 - NCT07483346RecruitingPhase 1
Testing IASO-782 for systemic lupus erythematosus
This trial tests a new medicine called IASO-782 for people with systemic lupus erythematosus (SLE). It aims to see if the drug can help control lupus symptoms when added to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06796569Recruiting
Blood test for inflammation in lupus patients
This study looks at a simple blood test (called the Systemic Immune Inflammatory Index) to see if it can help doctors understand how active lupus is in your body. It includes people with lupus, especially those with kidney involvement, to find better ways to track the disease.
Sohag, Sohag GovernorateAges 16 years+ - NCT07447986RecruitingPhase 2
Testing a New Injection for Lupus (SLE)
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT07444307RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses specially designed immune cells to target and destroy cells causing the disease.
Hefei, AnhuiAges 18–65 - NCT07425730Recruiting
Heart problems in childhood lupus study
This study looks at early heart function problems in children with lupus to find those at risk for severe disease. It may help doctors identify and treat severe lupus sooner.
Shanghai, Shanghai MunicipalityAges 7–17 - NCT07409181RecruitingPhase 2
Testing an experimental pill for active lupus (SLE)
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
Beverly Hills, CaliforniaAges 18–74
Hear when a new SLE (Systemic Lupus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sle (systemic lupus)?
- Yes. Clin2 currently lists 217 recruiting sle (systemic lupus) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sle (systemic lupus) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sle (systemic lupus) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.